venBio Global Strategic Fund II L.P.

venBio Global Strategic Fund II L.P. has filed trades across 5 companies (mainly through SEC (Form 4)), most often in Akero Therapeutics, Inc., Checkmate Pharmaceuticals, Inc. and Apellis Pharmaceuticals, Inc. Between 13 November 2017 and 16 May 2022, the trades on record add up to 56 filings.

Both buying and selling appear: 5 purchases worth €16.8M, against 45 sales worth €33.8M. Netting one side against the other leaves €17.0M of net selling. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. So far in 2022, the count stands at no purchases and 20 sales.

The median purchase comes to €3.5M. 5 out of 5 purchases came within 30 days of a purchase by at least one other insider of the same company. Purchases made close together by different insiders form what is called a cluster.

The record was last updated on 17 May 2022 with an open-market sale (€959k) in Checkmate Pharmaceuticals, Inc. The last insider purchase was made public on 29 April 2021, 2,019 days ago. Filings reach the SEC (Form 4) feed a median of 1 day after the trade. For comparison, the SEC allows two business days to file a Form 4. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.